SLP7111228 HCl | CAS#1449768-48-2 | SphK1 inhibitor

MedKoo Cat#: 206521 | Name: SLP7111228 HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SLP7111228 is a selective inhibitor of sphingosine kinase type 1 (SphK1). It consists of a pedant 1-guanidino-2-phenyloxadiazolylpyrrolidine group.

Chemical Structure

SLP7111228 HCl

CAS#1449768-48-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 206521

Name: SLP7111228 HCl

CAS#: 1449768-48-2 (HCl)

Chemical Formula: C22H34ClN5O

Exact Mass: 0.0000

Molecular Weight: 420.00

Elemental Analysis: C, 62.92; H, 8.16; Cl, 8.44; N, 16.68; O, 3.81

Price and Availability

Size	Price	Availability
1mg	USD 350.00	2 weeks
5mg	USD 550.00	2 weeks
10mg	USD 780.00	2 Weeks
25mg	USD 1,350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1449765-82-5 (free base) 1449768-48-2 (HCl)

Synonym

SLP7111228; SLP-7111228; SLP 7111228.

IUPAC/Chemical Name

(S)-2-((3-(4-octylphenyl)-1,2,4-oxadiazol-5-yl)methyl)pyrrolidine-1-carboximidamide hydrochloride

InChi Key

REAGUXWEQBFUPB-FYZYNONXSA-N

InChi Code

InChI=1S/C22H33N5O.ClH/c1-2-3-4-5-6-7-9-17-11-13-18(14-12-17)21-25-20(28-26-21)16-19-10-8-15-27(19)22(23)24;/h11-14,19H,2-10,15-16H2,1H3,(H3,23,24);1H/t19-;/m0./s1

SMILES Code

N=C(N1[C@H](CC2=NC(C3=CC=C(CCCCCCCC)C=C3)=NO2)CCC1)N.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, DMF, and ethanol

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SLP7111228 is a potent and selective inhibitor of SPHK1 with Ki values of 0.048 and >10 μM for SPHK1 and 2, respectively.

In vitro activity:

In BV2 mouse microglia cells, LPS induced transcription of both SphK1 and SphK2, and SLP7111228 and SLM6031434 strongly reduced LPS-induced TNFα and IL-1β production; the two SphKs were pro-inflammatory in BV2 cells in a non-redundant manner. Reference: Int J Mol Sci. 2023 May 9;24(10):8508. https://pubmed.ncbi.nlm.nih.gov/37239854/

In vivo activity:

In vivo application of SLP7111228 depressed blood S1P levels while SLP120701 increased levels of S1P. These compounds serve as a chemical toolkit for studying the impact of altering S1P levels and its potential implications in diseases. Reference: J Med Chem. 2015 Feb 26;58(4):1879-1899. https://pubmed.ncbi.nlm.nih.gov/25643074/

	Solvent	mg/mL	mM
Solubility
	DMF	12.5	29.76
	DMSO	30.0	71.43
	Ethanol	30.0	71.43

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 420.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Standoli S, Rapino C, Di Meo C, Rudowski A, Kämpfer-Kolb N, Volk LM, Thomas D, Trautmann S, Schreiber Y, Meyer Zu Heringdorf D, Maccarrone M. Sphingosine Kinases at the Intersection of Pro-Inflammatory LPS and Anti-Inflammatory Endocannabinoid Signaling in BV2 Mouse Microglia Cells. Int J Mol Sci. 2023 May 9;24(10):8508. doi: 10.3390/ijms24108508. PMID: 37239854; PMCID: PMC10217805. 2. Patwardhan NN, Morris EA, Kharel Y, Raje MR, Gao M, Tomsig JL, Lynch KR, Santos WL. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. J Med Chem. 2015 Feb 26;58(4):1879-1899. doi: 10.1021/jm501760d. Epub 2015 Feb 13. PMID: 25643074; PMCID: PMC4557804.

In vitro protocol:

In vivo protocol:

1. Patwardhan NN, Morris EA, Kharel Y, Raje MR, Gao M, Tomsig JL, Lynch KR, Santos WL. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. J Med Chem. 2015 Feb 26;58(4):1879-1899. doi: 10.1021/jm501760d. Epub 2015 Feb 13. PMID: 25643074; PMCID: PMC4557804.

1: Patwardhan NN, Morris EA, Kharel Y, Raje MR, Gao M, Tomsig JL, Lynch KR, Santos WL. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. J Med Chem. 2015 Feb 26;58(4):1879-99. doi: 10.1021/jm501760d. Epub 2015 Feb 13. PubMed PMID: 25643074; PubMed Central PMCID: PMC4557804.